HF 2022: CCM Therapy in Patients With HFpEF | Dr Cecilia Linde

Подробнее о видео

Watch on Radcliffe Cardiology:

In this short interview, Dr Cecilia Linde (Karolinska University, SE) shares the findings of the CCMHFpEF Study.
Originally presented at Heart Failure 22, this study aimed to evaluate the safety and efficacy of
cardiac contractility modulation therapy in heart failure patients with preserved ejection fraction (HFpEF).

Discussion Points:
1. Study Background
2. Study Design & Patient Population
3. CCM Therapy
4. Key Findings
5. Patient Recommendations
6. Conclusions
7. Next Steps

Recorded on-site at Heart Failure 2022, Madrid.
This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.